Ingemar Turesson
101 – 123 of 123
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- 3
- next »
- 2005
-
Mark
International Staging System for Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: Long-term follow-up
(
- Contribution to journal › Article
- 2004
-
Mark
MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: Evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
(
- Contribution to journal › Article
-
Mark
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
(
- Contribution to journal › Article
-
Mark
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival
(
- Contribution to journal › Article
-
Mark
Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma
(
- Contribution to journal › Article
-
Mark
High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation.
(
- Contribution to journal › Article
- 2003
-
Mark
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
(
- Contribution to journal › Article
-
Mark
Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
(
- Contribution to journal › Article
-
Mark
A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences.
(
- Contribution to journal › Article
-
Mark
Radiation therapy dose delivery
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
(
- Contribution to journal › Article
- 2002
-
Mark
Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy.
(
- Contribution to journal › Article
-
Mark
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase - a report from the Swedish CML Group
(
- Contribution to journal › Article
-
Mark
Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation
(
- Contribution to journal › Article
-
Mark
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
(
- Contribution to journal › Article
-
Mark
Sensitizing and protective substances in radiation therapy and predictive assays
(
- Contribution to journal › Article
- 1993
-
Mark
Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Hepatit C. Förekomst och relevans hos multitransfunderade patienter med hematologisk sjukdom
(
- Contribution to journal › Article
- 1982
-
Mark
Is occult atrial disorder a frequent cause of non-hemorrhagic stroke? Long-term ECG in 86 patients
(
- Contribution to journal › Article
- 1978
-
Mark
Non-secretory or low-secretory myeloma with intracellular kappa chains. Report of six cases and review of the literature
(
- Contribution to journal › Article
- 1977
-
Mark
Expression of protein HC on the plasma membrane of different human cell types
(
- Contribution to journal › Article
- 1976
-
Mark
Immunofluorescent demonstration of the presence of protein HC on the surface of human lymphocytes
(
- Contribution to journal › Article
- « previous
- 1
- 2
- 3
- next »